1-Methyl-4-phenyl-pyridinium increases S-adenosyl-L-methionine dependent phospholipid methylation

Pharmacology Biochemistry and Behavior

Volumn 70, Issue 1, 2001, Pages 105-114

  Lee, Eun Sook Y ^a   Charlton, Clivel G ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Lysophosphatidylcholine; Methylation; MPP+; MPTP; Parkinson's disease; Phosphatidylcholine; Phosphatidylethanolamine; Phospholipids; S adenosyl L methionine

Indexed keywords

1 ACETYLPYRIDINIUM; 1 ETHYL 4 PHENYLPYRIDINIUM; 1 METHYL 4 PHENYLPYRIDINIUM; 1 PROPYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,2,3,6 TETRAHYDRO 4 PHENYLPYRIDINE; 1,4 DIMETHYLPYRIDINIUM; 4 PHENYLPYRIDINIUM; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PYRIDINE DERIVATIVE; PYRIDINIUM DERIVATIVE; S ADENOSYLMETHIONINE; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SYNTHESIS; LIVER; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHOSPHOLIPID METHYLATION; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HERBICIDES; LIVER; MALE; METHYLATION; METHYLTRANSFERASES; MOTOR ACTIVITY; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY;

GYMNOMYZA SAMOENSIS;

EID: 0034873250     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(01)00588-3     Document Type: Article

References (56)

1. 1-Acyl-2-lysophosphatidylcholine transport across the blood-retina and blood-brain barrier
2. 2 and membrane-derived lipid second messengers in excitable membrane function and transcriptional activation of genes: Implication in cerebral ischemia and neuronal excitability
3. Mediators of injury in neurotrauma: Intracellular signal transduction and gene expression
4. Verteilung des 5-hydroxytryptamines (serotonin) im gehirn des enschen und sein verhalten bei patienten mit Parkinson-Syndrom
5. In vivo studies on pathways for the biosynthesis of lecithin in the rat
6. Choline and cholinergic neurons
7. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
8. +) decrease dopamine and increase acetylcholine in the mouse neostriatum
9. A parallel relationship between Parkinson's disease and an excess of S-adenosylmethionine-dependent biological methylation in the brain
10. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain
11. Tremor induced by S-adenosyl-L-methionine: Possible relation to L-dopa effects
12. Potential parkinsonism protoxicants within and without
13. Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins
14. Identification and properties of methyltransferases that synthesize phosphatidylcholine in rat brain synaptosomes
15. S-adenosyl-L-methionine decreases motor activity in the rat: Similarity to Parkinson's disease-like symptoms
16. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
17. Apoptosis and DNA degradation induced by 1-methyl-4-phenyl pyridinium in neurons
18. Dopaminergic neurotoxicity of MPTP in the mouse: A murine model of parkinsonism
19. Chronic alterations in jejunal myoelectric activity in rats due to MPTP
20. Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects
21. The formation of phospholipid by the hepatectomized dog as measured with radioactive phosphorus
22. Excitatory amino acids and MPTP toxicity
23. +-induced effects on body temperature exhibit age- and strain-dependence in mice
24. Identification of dopamine, noradrenaline and 5-hydroxytryptamine varicosities in a fraction containing nerve ending particles
25. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin
26. Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists
27. Reactive oxygen species and the central nervous system
28. Enzymatic methylation of phosphatidylethanolamine increases erythrocyte membrane fluidity
29. Phospholipid methylation and biological signal transmission
30. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine
31. Lecithin consumption increases acetylcholine concentrations in rat brain and adrenal gland
32. Dopamine (3-hydroxytyramine) and brain function
33. The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: Role of intracellular calcium
34. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
35. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey
36. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
37. Role of N-methyl-d-aspartate (NMDA) receptors in experimental catalepsy in rats
38. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain
39. +) in ventral mesencephalic-striatal co-culture in rat
40. 2/M transition
41. Isoquinoline neurotoxins in the brain and Parkinson's disease
42. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions
43. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine
44. Purification of phosphatidylethanolamine N-methyltransferase from rat liver
45. + analogues and related charged species
46. Neurochemical and behavioral features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease?
47. Effect of long-term administration of 1,2,3,4-tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in mice
48. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
49. Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms
50. Characterization of phospholipid methylation in rat brain myelin
51. Protein kinase C catalyses the phosphorylation and activation of rat liver phospholipid methyltransferase
52. N-methylation of pyridines and Parkinson's disease
53. Long-term levodopa in Parkinson's disease
54. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes
55. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs
56. 2